The use of the normal tissue non-complication probability (NTCP0) methodology as a new alternative of assessing side-effects in brachytherapy treatments.

LKB NTCP model NTCP binomial distribution brachytherapy side-effect

Journal

Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
ISSN: 1507-1367
Titre abrégé: Rep Pract Oncol Radiother
Pays: Poland
ID NLM: 100885761

Informations de publication

Date de publication:
2022
Historique:
received: 28 03 2022
accepted: 06 05 2022
entrez: 5 10 2022
pubmed: 6 10 2022
medline: 6 10 2022
Statut: epublish

Résumé

The NTCP methodology evaluating side-effects (S-Es) was initially used in radiotherapy (RT), and later was extended to brachytherapy (BT). The NTCP0 methodology has been recently introduced in RT. Given the advantages, this methodology could replace NTCP. Revisions of studies related to use of NTCP in the evaluations of S-Es in BT. Development of the first versions of two Matlab applications of the NTCP0 methodology. These applications have three options. Two of them employ the well-known aspects of a phenomenological model, or the probabilistic relationship between NTCP0 and total NTCP (TNTCP) that is the The NTCP0cal and NTCP0calDr Matlab applications have been developed, and respectively used for fractional continuous low dose-rate BT. NTCP0 is defined as the ratio of the number of patients without acute/late complications and total of them, and also can be obtained using our Matlab applications. NTCP0 works do not disregard the last 10-15 years of NTCP research; but NTCP0 was not considered during these years. A generic example was used for showing the variations of the late complications and NTCP0 for a BT treatment of a constant number of fractions and six different dose per fraction values.

Sections du résumé

Background UNASSIGNED
The NTCP methodology evaluating side-effects (S-Es) was initially used in radiotherapy (RT), and later was extended to brachytherapy (BT). The NTCP0 methodology has been recently introduced in RT. Given the advantages, this methodology could replace NTCP.
Materials and methods UNASSIGNED
Revisions of studies related to use of NTCP in the evaluations of S-Es in BT. Development of the first versions of two Matlab applications of the NTCP0 methodology. These applications have three options. Two of them employ the well-known aspects of a phenomenological model, or the probabilistic relationship between NTCP0 and total NTCP (TNTCP) that is the
Results UNASSIGNED
The NTCP0cal and NTCP0calDr Matlab applications have been developed, and respectively used for fractional continuous low dose-rate BT.
Conclusions UNASSIGNED
NTCP0 is defined as the ratio of the number of patients without acute/late complications and total of them, and also can be obtained using our Matlab applications. NTCP0 works do not disregard the last 10-15 years of NTCP research; but NTCP0 was not considered during these years. A generic example was used for showing the variations of the late complications and NTCP0 for a BT treatment of a constant number of fractions and six different dose per fraction values.

Identifiants

pubmed: 36196423
doi: 10.5603/RPOR.a2022.0063
pii: rpor-27-4-602
pmc: PMC9521694
doi:

Types de publication

Journal Article

Langues

eng

Pagination

602-609

Informations de copyright

© 2022 Greater Poland Cancer Centre.

Déclaration de conflit d'intérêts

Conflict of interest None declared.

Références

Int J Radiat Biol. 2020 Jul;96(7):847-850
pubmed: 32163306
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S130-4
pubmed: 20171507
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S77-85
pubmed: 20171522
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S64-9
pubmed: 20171520
BMC Cancer. 2018 May 18;18(1):575
pubmed: 29776390
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S42-9
pubmed: 20171517
Med Phys. 2012 Mar;39(3):1386-409
pubmed: 22380372
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S108-15
pubmed: 20171504
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S86-93
pubmed: 20171523
Radiother Oncol. 2019 Jun;135:100-106
pubmed: 31015154
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S94-100
pubmed: 20171524
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S101-7
pubmed: 20171503
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S28-35
pubmed: 20171514
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S20-7
pubmed: 20171513
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S123-9
pubmed: 20171506
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S58-63
pubmed: 20171519
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S116-22
pubmed: 20171505
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S70-6
pubmed: 20171521
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S50-7
pubmed: 20171518

Auteurs

Terman Frometa-Castillo (T)

Owner at Statistical models project, LLC, Chicago, IL, United States.

Anil Pyakuryal (A)

University of District of Columbia, Division of Science and Mathematics, Washington, DC, United States.

Ganesh Narayanasamy (G)

University of Arkansas for Medical Sciences, Little Rock, United States.

Asghar Mesbahi (A)

Tabriz University of Medical Sciences, Tabriz, Iran.

Amadeo Wals-Zurita (A)

Hospital Universitario Virgen Macarena, Sevilla, Spain.

Classifications MeSH